Détail - canceropole-wordpress

[Adherence to lung cancer screening by low-dose chest CT: Results of the first round of screening in the Multicenter Interventional DeCanPHaR Study].

Strentz P, Rinaldo F, Jacquet-Pierroulet C, Baumann E, Fonne S, Bizot C, Hammas K, Palpacuer C, Debieuvre D,

Rev Mal Respir. 2026 03 12;:

Association of sleep-related hypoxemia with survival in patients with non-small cell lung cancer - the NEOSAS-GFPC study group.

Justeau G, Greillier L, Vinas F, Falchero L, Bylicki O, Bernardi M, Martin F, Simon I, Debieuvre D, Locher C, Bizieux-Thaminy A, Levrat V, Fry S, Guguen C, Goutorbe F, Masson P, Soyez F, Chouaid C, Saulnier P, Gagnadoux F

Chest. 2026 03 9;:

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.

Lin SH, Kahangire DA, Nagar SP, Ahn MJ, Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M, Davis KL, Sandelin M, Veluswamy RR

Lung Cancer. 2026 02 28;215:109348

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial.

Brosseau S, Etienne H, Peoc'h K, Langlais A, Blanché H, Foucher P, Barlesi F, Domas J, Girard P, Scherpereel A, Dumont P, Derollez M, Quoix E, Debieuvre D, Deleuze JF, Leçon-Malas V, Zalcman G, Westeel V, Mordant P

Lung Cancer. 2026 02 24;215:109345

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.

Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M

Adv Ther. 2026 02 13;:

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial.

Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC

J Thorac Oncol. 2026 02 12;:103609

Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.

Gounant V, Greillier L, Mascaux C, Pinquie F, Carmier D, Moreau L, Roch B, Debieuvre D, Dhalluin X, Giroux-Leprieur E, Berton E, Rabeau A, Raimbourg J, Dixmier A, Naltet C, Khalil A, Ezzeddine L, El Hajjam M, Langlais A, Morin F, Westeel V, Zalcman G, Duruisseaux M

JTO Clin Res Rep. 2025 12;6(12):100908

Final 3-year results from the EVIDENS study, an observational study of nivolumab in non-small cell lung cancer.

Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Asselain B, Audigier-Valette C, Brellier F, Cotté FE, Khalife Y, Pérol M

Oncoimmunology. 2025 12;14(1):2492932

Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice.

Chouaid C, Giraud P, Wislez M, Pichon E, Stancu A, Debieuvre D, Girard N, Pérol M, Quantin X, Ano S, Grela F, Goyard N, Fore M, Magne F, Pante V, Lemonnier-Videau L, Falchero L

Respir Med Res. 2025 10 9;88:101216

Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysis.

Amrane K, Cabarrou B, Justeau G, Schneider S, Quantin X, Falchero L, Bigot F, Ferrari V, Guisier F, Girard N, Lena H, Dansin E, Madroszyk A, Bizieux A, Debieuvre D, Perol M, Simoneau Y, Bosquet L, Descourt R, Chouaïd C

ESMO Open. 2025 07 23;10(8):105343

Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.

Debieuvre D, Falchero L, Molinier O, Couraud S, Cortot A, Meyer N, Asselain B, Auvray E, Templement-Grangerat D, Bizieux A, Tredaniel J, Schneider S, Auliac JB, Bylicki O, Letierce A, Morel H

NEJM Evid. 2025 07;4(7):EVIDoa2400443

Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020.

Couraud S, Molinier O, Sabatini M, Thomassin S, Haouachi R, Levrat V, Ghalloussi-Tebai H, Belle A, Mosser L, Larive S, Bedossa A, Letierce A, Morel H, Debieuvre D,

Respir Med Res. 2025 05 8;88:101174

Clinical characteristics and management of long survivors in extensive stage small cell lung cancer.

Gobbini E, Diallo MH, Pasquier D, Schneider S, Chouaid C, Debieuvre D, Quantin X, Gervais R, Valette CA, Justeau G, Ravoire M, Madroszyk A, Pichon E, Falchero L, Simoneau Y, Bylicki O, Baranzelli A, Bosquet L, Pérol M, Girard N

Lung Cancer. 2025 03 16;202:108499

[Lung cancer epidemiology: evolution over the last twenty years].

Debieuvre D

Bull Cancer. 2025 03;112(3S1):3S3-3S15

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis.

Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

Front Oncol. 2025 02 20;15:1526931

LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer.

Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D, Dot JM, Duruisseaux M, Fournel P, Odier L, Demolombe S, Bizieux-Thaminy A, Peytier A, Schott R, Hominal S, Tissot C, Bombaron P, Metzger S, Donnat M, Ortiz-Cuaran S, Rosenfeld N, Pipinikas C, Saintigny P, Pérol M

J Thorac Oncol. 2024 12 16;:

Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort.

Swalduz A, Beau-Faller M, Planchard D, Mazieres J, Bayle-Bleuez S, Debieuvre D, Fallet V, Geier M, Cortot A, Couraud S, Daniel C, Domblides C, Pichon E, Fabre E, Larivé S, Lerolle U, Tomasini P, Wislez M, Missy P, Morin F, Westeel V, Auliac JB

Lung Cancer. 2024 11 26;199:108038

COVID-19 among lung cancer patients: Data from a real-life prospective French multicentric study.

Molinier O, Pinsolle J, Bizieux Thaminy A, Schneider S, Godbert B, Portel L, Hugues F, Dayen C, Obert J, Dujon C, Dumont P, Julien S, Meyer N, Letierce A, Morel H, Debieuvre D,

Respir Med Res. 2024 11;86:101093

Optimizing Treatment Strategies for -Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights.

Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X

Cancers (Basel). 2024 10 23;16(21):

Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.

Falchero L, Meyer N, Molinier O, Al Freijat F, Pegliasco H, Lecuyer E, Stoven L, Belmont L, Loutski S, Maincent C, Blanchet-Legens AS, Mairovitz A, Meniai F, Hominal S, Letierce A, Morel H, Debieuvre D

Eur J Cancer. 2024 08 14;210:114277

Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database.

Cabart M, Mourey L, Pasquier D, Schneider S, Léna H, Girard N, Chouaid C, Schott R, Hiret S, Debieuvre D, Quantin X, Madroszyk A, Dubray-Longeras P, Pichon E, Baranzelli A, Justeau G, Pérol M, Bosquet L, Cabarrou B

J Geriatr Oncol. 2024 07 26;:101819

Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts.

Hoang TCT, Debieuvre D, Bravard AS, Martinez S, Le Garff G, Jeandeau S, Petit L, Marquette D, Amrane K, Demontrond P, Tiercin M, Jarjour B, Turlotte A, Masson P, Jaafar M, Hauss PA, Morel H,

ESMO Open. 2024 06 6;9(6):103594

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.

Thomas QD, Quantin X, Lemercier P, Chouaid C, Schneider S, Filleron T, Remon-Masip J, Perol M, Debieuvre D, Audigier-Valette C, Justeau G, Loeb A, Hiret S, Clement-Duchene C, Dansin E, Stancu A, Pichon E, Bosquet L, Girard N, Du Rusquec P

ESMO Open. 2024 06 3;9(6):103473

Randomized Open-Label Controlled Study of Cancer Vaccine OSE2101 Versus Chemotherapy in HLA-A2-positive Patients with Advanced Non-Small Cell Lung Cancer with Resistance to Immunotherapy: ATALANTE-1.

Besse B, Felip E, Campelo RG, Cobo M, Mascaux C, Madroszyk A, Cappuzzo F, Hilgers W, Romano G, Denis F, Viteri S, Debieuvre D, Galetta D, Baldini E, M Razaq,Robinet G, Maio M, Delmonte A, Roch B, Masson P, Schuette W, Zer A, Remon J, Costantini D, Vasseur B, Dziadziuszko R, Giaccone G,

Ann Oncol. 2023 08 1;:

Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors.

Heudel PE, de Montfort A, Debieuvre D, Chouaid C, Carton M, Audigier-Valette C, Filleron T, Chabaud S, Stancu A, Quantin X, Hiret S, Bosquet L, Blay JY

Lung Cancer. 2023 06 16;182:107280

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting.

Belaroussi Y, Bouteiller F, Bellera C, Pasquier D, Perol M, Debieuvre D, Filleron T, Girard N, Schott R, Mathoulin-Pélissier S, Martin AL, Cousin S

Sci Rep. 2023 06 13;13(1):9584

ICU admission for solid cancer patients treated with immune checkpoint inhibitors.

Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, Seguin A, Kouatchet A, Delaunay M, Debieuvre D, Duchemann B, Rousseau-Bussac G, Nyunga M, Grimaldi D, Levrat A, Azoulay E, Lemiale V

Ann Intensive Care. 2023 04 18;13(1):29

Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.

Valette CA, Filleron T, Debieuvre D, Lena H, Pérol M, Chouaid C, Simon G, Quantin X, Girard N

Respir Med Res. 2023 03 27;84:101012

Enrolment of older adults with advanced or metastatic non-small cell lung cancer in first-line clinical trials in the multicentre ESME cohort.

Bringuier M, Carton M, Debieuvre D, Pasquier D, Perol M, Filleron T, Léna H, Quantin X, Simon G, Baldini C

J Geriatr Oncol. 2023 01 17;14(2):101423

Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study.

Portel L, Fabry-Vendrand C, Texier N, Schwartz D, Capdepon A, Thabut G, Debieuvre D

J Asthma Allergy. 2023 01 4;16:9-21

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.

Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté FE, Audigier-Valette C, Griesinger F

Cancers (Basel). 2022 12 13;14(24):

Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.

Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, Morel H, Duval Y, Asselain B, Letierce A, Trédaniel J, Auliac JB, Bylicki O, Moreau L, Fore M, Corre R, Couraud S, Cortot A, ,

Lancet Reg Health Eur. 2022 11;22:100492

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.

Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V

J Clin Oncol. 2022 09 7;:JCO2200096

Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.

Westeel V, Foucher P, Scherpereel A, Domas J, Girard P, Trédaniel J, Wislez M, Dumont P, Quoix E, Raffy O, Braun D, Derollez M, Goupil F, Hermann J, Devin E, Barbieux H, Pichon E, Debieuvre D, Ozenne G, Muir JF, Dehette S, Virally J, Grivaux M, Lebargy F, Souquet PJ, Freijat FA, Girard N, Courau E, Azarian R, Farny M, Duhamel JP, Langlais A, Morin F, Milleron B, Zalcman G, Barlesi F

Lancet Oncol. 2022 08 11;:

French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version.

Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P

Respir Med Res. 2022 08 4;83:100948

[Management of immunotherapy in patients with non-small cell lung cancer presenting durable oncological response].

Storme S, Debieuvre D, Souquet PJ, Toffart AC, Couraud S

Rev Mal Respir. 2022 07 28;:

Mid-term pulmonary sequelae after hospitalisation for COVID-19: The French SISCOVID cohort.

Calcaianu G, Degoul S, Michau B, Payen T, Gschwend A, Fore M, Iamandi C, Morel H, Oster JP, Bizieux A, Nocent-Ejnaini C, Carvallo C, Romanet S, Goupil F, Leurs A, Legrand MG, Portel L, Claustre J, Calcaianu M, Bresson D, Debieuvre D

Respir Med Res. 2022 06 14;82:100933

[French practical guidelines for the diagnosis and management of IPF - 2021 update, short version].

Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P,

Rev Mal Respir. 2022 Mar 14;:

FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.

Debieuvre D, Dayen C, Dixmier A, Pau D, Sibley-Revelat A, Greenwood W, Gally S, Falchero L

Lung Cancer. 2021 Dec 18;164:1-7

Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.

Souquet PJ, Audigier-Valette C, Molinier O, Cortot A, Margery J, Moreau L, Gervais R, Barlesi F, Pichon E, Zalcman G, Dumont P, Girard N, Poudenx M, Mazières J, Cadranel J, Debieuvre D, Dauba J, Langlais A, Morin F, Moro-Sibilot D, Westeel V, Pérol M

Lung Cancer. 2021 Nov 30;164:84-90

Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort.

Girard N, Perol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C

Lung Cancer. 2021 Nov 6;162:119-127

A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes.

Chouaid C, Filleron T, Debieuvre D, Pérol M, Girard N, Dansin E, Lena H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Hiret S, Pichon E, Clément-Duchêne C, Chenuc G, Simon G, Bosquet L, QUantin X

Target Oncol. 2021 Oct 18;:

[Severe adult asthma and treatment adherence: Results of the FASE-CPHG study].

Maurer C, Raherison-Semjen C, Lemaire B, Didi T, Nocent-Ejnaini C, Parrat E, Prudhomme A, Oster JP, Coëtmeur D, Debieuvre D, Portel L

Rev Mal Respir. 2021 Oct 11;:

Management of lung cancer patients' quality of life in clinical practice: a Delphi study.

Westeel V, Bourdon M, Cortot AB, Debieuvre D, Toffart AC, Acquadro M, Arnould B, Lambert J, Cotte FE, Gaudin AF, Lemasson H

ESMO Open. 2021 Aug 10;6(4):100239

First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.

Cortot AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, Charpentier S, Denis MG, Cadranel J

Clin Cancer Res. 2021 May 24;:

FASE-CPHG Study: identification of asthma phenotypes in the French Severe Asthma Study using cluster analysis.

Raherison-Semjen C, Parrat E, Nocent-Eijnani C, Mangiapan G, Prudhomme A, Oster JP, Aperre de Vecchi C, Maurer C, Debieuvre D, Portel L,

Respir Res. 2021 May 4;22(1):136

Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.

Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M

Lung Cancer. 2021 Apr 30;:

[Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020].

Andrejak C, Cottin V, Crestani B, Debieuvre D, Gonzalez-Bermejo J, Morelot-Panzini C, Stach B, Uzunhan Y, Maitre B, Raherison C

Rev Mal Respir. 2020 Nov 27;:

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.

Blons H, Oudart JB, Merlio JP, Debieuvre D, de Fraipont F, Audigier-Valette C, Escande F, Hominal S, Bringuier PP, Fraboulet-Moreau S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M,

Lung Cancer. 2020 Nov 13;:

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.

Payen T, Trédaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec JL, Molinier O, Debieuvre D

Respir Med Res. 2020 Nov 1;80:100795

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).

Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T,

Eur J Cancer. 2020 Oct 8;141:62-81

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

Quoix E, Audigier-Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Moreau L, Madelaine J, Dumont P, Margery J, Debieuvre D, Renault PA, Pujol JL, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ

Eur. J. Cancer. 2020 Sep 5;138:193-201

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by Mutation Subtypes.

Ruppert AM, Beau-Faller M, Debieuvre D, Ouafik L, Westeel V, Rouquette I, Mazières J, Bringuier PP, Monnet I, Escande F, Ricordel C, Merlio JP, Janicot H, Lemoine A, Foucher P, Poudenx M, Morin F, Langlais A, Souquet PJ, Barlesi F, Wislez M

JTO Clin Res Rep. 2020 Sep;1(3):100052

[Cerebral air embolism: A rare complication of flexible fiberoptic bronchoscopy].

Agossou M, Holtea-Souty D, Fore M, Vuillemin C, Debieuvre D

Rev Mal Respir. 2020 Aug 27;:

[Guide for follow-up of patients with SARS-CoV-2 pneumonia. Management proposals developed by the French-language Respiratory Medicine Society. Version of 10 May 2020].

Andrejak C, Blanc FX, Costes F, Crestani B, Debieuvre D, Perez T, Philippe B, Plantier L, Schlemmer F, Sesé L, Stach B, Uzunhan Y, Zanetti C, Zysman M, Raherison C, Maitre B

Rev Mal Respir. 2020 May 14;:

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.

Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Pérol M

Oncoimmunology. 2020 Apr 12;9(1):1744898

[Physical activity in severe asthma: Results of the FASE-CPHG Study].

Coëtmeur D, Parrat É, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, Vecchi CA, Maurer C, Raherison C, Debieuvre D, Portel L

Rev Mal Respir. 2020 Apr 7;:

A microsimulation model to assess the economic impact of immunotherapy in non-small cell lung cancer.

Legoupil C, Debieuvre D, Marabelle A, Michiels S, Kapso R, Besse B, Bonastre J

ERJ Open Res. 2020 Apr;6(2):

Randomized phase II trial evaluating treatment with EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC: IFCT-1003 LADIE trial.

Mazieres J, Barlesi F, Rouquette I, Molinier O, Besse B, Monnet I, Audigier-Valette C, Toffart AC, Renault PA, Fraboulet S, Hiret S, Mennecier B, Debieuvre D, Westeel V, Masson P, Madroszyk-Flandin A, Pichon E, Cortot AB, Amour E, Morin F, Zalcman G, Moro-Sibilot D, Souquet PJ

Clin. Cancer Res.. 2020 Mar 6;:

Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients.

Molinier O, Goupil F, Debieuvre D, Auliac JB, Jeandeau S, Lacroix S, Martin F, Grivaux M

Respir Med Res. 2019 Oct 28;77:46-54

FASE-CPHG study: a panoramic snapshot of difficult-to-treat, severe asthma in French nonacademic hospitals.

Portel L, Parrat E, Nocent-Ejnaini C, Mangiapan G, Prud'homme A, Oster JP, Aperre de Vecchi C, Maurer C, Raherison C, Debieuvre D

ERJ Open Res. 2019 Oct;5(4):

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial.

Bennouna J, Girard N, Audigier-Valette C, le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG

Clin Lung Cancer. 2019 Oct 1;:

Metastatic NSCLC: Clinical, molecular, and therapeutic factors associated with long-term survival.

Asselain B, Barrière JR, Clarot C, Vabre JP, Gentil Le Pecq B, Duval Y, Thomas P, Herman D, Grivaux M, Debieuvre D

Respir Med Res. 2019 Jul 10;76:38-44

[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].

Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M

Rev Mal Respir. 2019 Jun 13;:

Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.

Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D,

Eur. J. Cancer. 2019 Jun 7;116:86-97

Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: The EVIDENS study.

Pérol M, Dixmier A, Barlesi F, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Asselain B, Cotté FE, Lamoureux P, Karam N, Ozan N, Calvet C, Bryan B, Allan V, Audigier Valette C

Ann. Oncol.. 2019 Apr;30 Suppl 2:ii48

Real-world treatment patterns, clinical practice and outcomes for locally advanced, non resectable, non-small cell lung cancer from the French ESME Lung database.

Girard N, Pérol M, Simon G, Audigier Valette C, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C

Ann. Oncol.. 2019 Apr;30 Suppl 2:ii34

Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.

Antoun S, Morel H, Souquet PJ, Surmont V, Planchard D, Bonnetain F, Foucher P, Egenod T, Krakowski I, Gaudin H, Debieuvre D

J Cachexia Sarcopenia Muscle. 2019 Apr 1;:

Evidence of slight improvement in five-year survival in non-small-cell lung cancer over the last 10 years: Results of the French KBP-CPHG real-world studies.

Debieuvre D, Locher C, Asselain B, Dayen C, Molinier O, Falchero L, Dujon C, Delclaux B, Grivaux M

Bull Cancer. 2019 Feb 22;:

The Importance of Apneic Events in Obstructive Sleep Apnea Associated with Acute Coronary Syndrome.

Calcaianu G, Bresson D, Calcaianu M, Morisset B, El-Nazer T, Deodati C, Virot E, Holtea D, Iamandi C, Debieuvre D

Sleep Disord. 2019 ;2019:6039147

Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.

Morel H, Raynard B, d'Arlhac M, Hauss PA, Lecuyer E, Oliviero G, Marty C, Gury JP, Asselain B, Grivaux M, Debieuvre D

Lung Cancer. 2018 Dec;126:55-63

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study.

Scherpereel A, Durand-Zaleski I, Cotté FE, Fernandes J, Debieuvre D, Blein C, Gaudin AF, Tournier C, Vainchtock A, Chauvin P, Souquet PJ, Westeel V, Chouaïd C

BMC Cancer. 2018 Oct 22;18(1):1013

EVIDENS: An observational study of nivolumab-treated patients in advanced non-small cell lung cancer (NSCLC) in a real-world setting: Initial results on 1394 patients.

Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Asselain B, Dumont A, Lamoureux P, Goyard N, Moro-Sibilot D, Perol M, Barlesi F, Audigier Valette C

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii532

Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial.

Quoix E, Audigier Valette C, Lavolé A, Molinier O, Westeel V, Barlesi F, Le Treut J, Pichon E, Dauba J, Otto J, Dumont P, Moreau L, Madelaine J, Margery J, Debieuvre D, Renault PA, Langlais A, Morin F, Moro-Sibilot D, Souquet PJ

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii744-viii745

Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study.

Blons H, Oudart JB, Merlio JP, Hominal S, de Fraipont F, Debieuvre D, Escande F, Audigier Valette C, Bringuier PP, Moreau Fraboulet S, Ouafik L, Moro-Sibilot D, Lemoine A, Langlais A, Missy P, Morin F, Souquet PJ, Barlesi F, Cadranel J, Beau-Faller M

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii39-viii40

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet PJ

ESMO Open. 2018 ;3(5):e000394

New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases.

Dayen C, Debieuvre D, Molinier O, Raffy O, Paganin F, Virally J, Larive S, Desurmont-Salasc B, Perrichon M, Martin F, Grivaux M

J Thorac Dis. 2017 Dec;9(12):5101-5111

Impact of distance from surgery department on the outcome of patients followed for non-small-cell lung cancer in the respiratory department of nonacademic hospitals: Results of the KBP-2010-study.

Debieuvre D, Fraboulet G, Duvert B, Piquet J, Goarant E, Sandron D, Mouroux-Rotomondo C, Borrel B, Genety C, Kassem GJ, Grivaux M

Bull Cancer. 2017 Sep;:

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F

Eur. Respir. J.. 2017 Aug;50(2):

Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M,

Ann. Oncol.. 2017 Jul;:

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.

Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC,

Ann. Oncol.. 2017 Feb;:

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G

Oncotarget. 2017 Jan;8(3):4313-4329

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study).

Chouaïd C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin AF, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté FE, Souquet PJ

PLoS ONE. 2017 ;12(8):e0182798

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

Fiteni F, Anota A, Bonnetain F, Oster JP, Pichon E, Wislez M, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Molinier O, Dansin E, Poudenx M, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V

Eur. Respir. J.. 2016 Sep;48(3):861-72

[Relationship between primary lung cancer and tobacco consumption. Results of the KBP-2010-CPHG study by the French College of General Hospital Respiratory Physicians].

Coëtmeur D, Leveiller G, Frappat V, Martin M, Peureux M, Dehette S, Carbonnelle M, Dayen C, Debieuvre D, Grivaux M

Rev Mal Respir. 2016 Sep;33(7):583-93

[One-year survival improvement in lung cancer in France. Results of the prospective real life studies KBP-2000-CPHG and KBP-2010-CPHG].

Grivaux M, Duvert B, Ferrer-Lopez P, Hominal S, Goarant E, Brichet-Martin A, Romand P, Fournier E, Asselain B, Debieuvre D

Rev Pneumol Clin. 2016 May;72(3):163-70

Early mortality in lung cancer: French prospective multicentre observational study.

Grivaux M, Debieuvre D, Herman D, Lemonnier C, Marcos JM, Crequit J, Vuillermoz-Blas S, Barre P, Saillour M, Martin F

BMC Pulm Med. 2016 Apr;16:45

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).

Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G,

Lancet. 2016 Apr;387(10026):1415-26

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM

Lancet Oncol.. 2016 Feb;17(2):212-23

The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart.

Debieuvre D, Oster JP, Riou R, Berruchon J, Levy A, Mathieu JP, Dumont P, Leroy-Terquem E, Tizon-Couetil V, Martin F, Grivaux M

Lung Cancer. 2016 Jan;91:1-6

Access to Innovative Drugs in Patients with Metastatic Lung Cancer in French Public Hospitals (the Territoire Study).

Scherpereel A, Fernandes J, Cotte F, Blein C, Debieuvre D, Durand-Zaleski I, Gaudin A, Ozan N, Saitta B, Souquet P, Vainchtock A, Westeel V, Chouaid C

Value Health. 2015 Nov;18(7):A341

No impact of passive smoke on the somatic profile of lung cancers in never-smokers.

Couraud S, Debieuvre D, Moreau L, Dumont P, Margery J, Quoix E, Duvert B, Cellerin L, Baize N, Taviot B, Coudurier M, Cadranel J, Missy P, Morin F, Mornex JF, Zalcman G, Souquet PJ

Eur Respir J. 2015 Mar 5. pii: ERJ-00973-2014.

ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?

Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F

Expert Rev Anticancer Ther. 2015 Feb;15(2):225-33

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).

Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morere JF

J Geriatr Oncol. 2015 Feb 16. pii: S1879-4068(15)00009-0

[Ten-year evolution in non-small-cell lung cancer according to sex. Results of the KBP-2010-CPHG study by the College of General Hospital Respiratory Physicians].

Debieuvre D, Locher C, Neidhardt AC, Goupil F, Lemaire B, Blanchet-Legens AS, Renault D, Tavernier JY, Tagu P, Mahmoud H, Figueredo M, Grivaux M

Rev Mal Respir. 2014 Nov;31(9):805-16

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F

Bull Cancer. 2014 Sep;101(9):823-31

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G

Eur Respir J. 2014 Jan;43(1):240-9

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

Westeel V, Quoix E, Puyraveau M, Lavole A, Braun D, Laporte S, Bigay-Game L, Pujol JL, Ozenne G, Riviere A, Douillard JY, Lebeau B, Debieuvre D, Poudenx M, David P, Molinier O, Zalcman G, Lemarie E, Morin F, Depierre A, Milleron B

Eur J Cancer. 2013 Aug;49(12):2654-64

Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies.

Locher C, Debieuvre D, Coetmeur D, Goupil F, Molinier O, Collon T, Dayen C, Le Treut J, Asselain B, Martin F, Blanchon F, Grivaux M

Lung Cancer. 2013 Jul;81(1):32-8

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G

Clin Cancer Res. 2012 May 15;18(10):2976-86

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G

Mol Cancer Ther. 2012 May;11(5):1203-13

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.

Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, Koralewski P, Breton JL, Stoelben E, Braun D, Debieuvre D, Lena H, Buyse M, Chenard MP, Acres B, Lacoste G, Bastien B, Tavernaro A, Bizouarne N, Bonnefoy JY, Limacher JM

Lancet Oncol. 2011 Nov;12(12):1125-33

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavole A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducolone A, Lebitasy MP, Baudrin L, Laporte S, Milleron B

Lancet. 2011 Sep 17;378(9796):1079-88

Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).

Morere JF, Brechot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlesi F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D

Lung Cancer. 2010 Dec;70(3):301-7

[Study KBP-2010-CPHG: inclusion of new cases of primary lung cancer diagnosed in general hospital pneumology departments between 1st January and 31 December 2010].

Grivaux M, Locher C, Bombaron P, Collon T, Coetmeur D, Dayen C, Debieuvre D, Goupil F, Le Treut J, Martin F, Molinier O, Asselain B, Zureik M, Blanchon F

Rev Pneumol Clin. 2010 Dec;66(6):375-82

[Intrahospital mortality during acute exacerbations of COPD. Study EABPCO-CPHG of the College of the Lung specialists of General hospitals (CPHG)].

Chavaillon JM, Lerousseau L, David P, Martin F, Lamour C, Beraud A, Sleiman C, Debieuvre D, Just N, Senechal F, Camuset J, Mornet M, Fesq G, Zureik M, Roche N, Blanchon F, Piquet J

Rev Mal Respir. 2010 Sep;27(7):709-16

Rurality and survival differences in lung cancer: a large population-based multivariate analysis.

Pozet A, Westeel V, Berion P, Danzon A, Debieuvre D, Breton JL, Monnier A, Lahourcade J, Dalphin JC, Mercier M

Lung Cancer. 2008 Mar;59(3):291-300

How to treat the relapse of NSCLC after surgery and chemotherapy? IFTC 0702 randomized phase III study

Moro-Sibilot D, Barlesi F, Timsit JF, Debieuvre D, Fournel P, Gervais R, Mazieres J, Milleron B, Morin F, Perol M, Soria JC, Souquet PJ, Vergnenegre A, Zalcman G

Rev Mal Respir. 2008 Jan;25(1):91-6.

[What treatment for a patient of PS 2-3 with stage IV non-small cell lung cancer?]

Moro-Sibilot D, Pluquet E, Zalcman G, Brechot JM, Souquet PJ, Debieuvre D, Morin F, Morere JF

Rev Mal Respir. 2007 Oct;24(8 Pt 2):6S120-4.

Acute exacerbations of COPD admitted to hospital: predictive factors of 3 year mortality

Piquet J, Maurer C, Barbieux H, Chavaillon JM, Debieuvre D, Lebas FX, Maetz E, Marcos M, Moncelly L, Orlando JP, Viau F, Zureik M, Marsal L, Roche N, Blanchon F

Rev Mal Respir. 2007 Sep;24(7):909-16.

Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.

Pujol JL, Milleron B, Molinier O, Quoix E, Depierre A, Breton JL, Gervais R, Debieuvre D, Hominal S, Namouni F, Tonelli D

J Thorac Oncol. 2006 May;1(4):328-34

Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.

Westeel V, Breton JL, Braun D, Quoix E, Milleron B, Debieuvre D, Jacoulet P, Germa C, Kayitalire L, Depierre A

Lung Cancer. 2006 Mar;51(3):347-55

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, Milleron B, Debieuvre D, Castera D, Souquet PJ, Moro-Sibilot D, Lemarie E, Kessler R, Janicot H, Braun D, Spaeth D, Quantin X, Clary C

Ann Oncol. 2005 Apr;16(4):602-10

Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.

Westeel V, Quoix E, Moro-Sibilot D, Mercier M, Breton JL, Debieuvre D, Richard P, Haller MA, Milleron B, Herman D, Level MC, Lebas FX, Puyraveau M, Depierre A

J Natl Cancer Inst. 2005 Apr 6;97(7):499-506.

[Treatment of anemia and bone metastasis in metastatic non-small-cell lung cancer. A French survey]

Brechot JM, Roche N, Marichy C, Lebeau B, Debieuvre D, Darneau G, Coste E, Grivaux M, Falchero L, Vlastos F, Souquet PJ

Rev Pneumol Clin. 2005 Feb;61(1 Pt 1):23-9.

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P, Quoix E

Ann Oncol. 2005 Jan;16(1):90-6.

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.

Quoix E, Lebeau B, Depierre A, Ducolone A, Moro-Sibilot D, Milleron B, Breton JL, Lemarie E, Pujol JL, Brechot JM, Zalcman G, Debieuvre D, Vaylet F, Vergnenegre A, Clouet P

Ann. Oncol.. 2004 Jan;15(1):38-44

Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study.

Quoix E, Breton JL, Daniel C, Jacoulet P, Debieuvre D, Paillot N, Kessler R, Moreau L, Coëtmeur D, Lemarié E, Milleron B

Ann. Oncol.. 2001 Jul;12(7):957-62

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

Pujol JL, Daurès JP, Rivière A, Quoix E, Westeel V, Quantin X, Breton JL, Lemarié E, Poudenx M, Milleron B, Moro D, Debieuvre D, Le Chevalier T

J. Natl. Cancer Inst.. 2001 Feb;93(4):300-8

Dr DEBIEUVRE Didier

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Recherche

Publications

Retrouvez aussi